產(chǎn)品[
CRL-2551 Panc 08.13 人胰腺癌細(xì)胞
]資料
如果您對(duì)該產(chǎn)品感興趣的話,可以
產(chǎn)品名稱:
CRL-2551 Panc 08.13 人胰腺癌細(xì)胞
產(chǎn)品型號(hào):
CRL-2551
產(chǎn)品廠商:
美國標(biāo)準(zhǔn)生物品收藏中心（ATCC）
產(chǎn)品文檔:
無相關(guān)文檔
簡單介紹
CRL-2551 Panc 08.13 人胰腺癌細(xì)胞，原代細(xì)胞|細(xì)胞系|細(xì)胞株|菌種；細(xì)胞庫管理規(guī)范，提供的細(xì)胞株背景清楚，提供參考文獻(xiàn)和Z優(yōu)培養(yǎng)條件！
CRL-2551 Panc 08.13 人胰腺癌細(xì)胞
的詳細(xì)介紹
CRL-2551 Panc 08.13 人胰腺癌細(xì)胞
|
|
CRL-2551?
|
|
$417.00
|
|
|
Panc 08.13
|
|
|
EM Jaffee
|
|
Biosafety Level:
|
1
|
|
|
frozen
|
|
Medium & Serum:
|
See Propagation
|
|
|
adherent
|
|
|
Homo sapiens (human)
|
|
|
epithelial
|
|
|
Organ: pancreas
Disease: adenocarcinoma
|
|
|
cytokeratins 7 and 18 [50655]
|
|
|
In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
|
|
|
|
|
Yes
|
|
|
K-ras +
|
|
|
MHC class I +; MHC class II - [50655]
|
|
|
Amelogenin: X
CSF1PO: 11
D13S317: 13
D16S539: 13
D5S818: 13,14
D7S820: 11
THO1: 6,9.3
TPOX: 8,12
vWA: 18
|
|
|
85 years
|
|
|
male
|
|
|
White
|
|
|
ATCC complete growth medium: RPMI 1640 medium with 2 mM L-glutamine adjusted to contain 1.5 g/L sodium bicarbonate, 4.5 g/L glucose, 10 mM HEPES, and 1.0 mM sodium pyruvate and supplemented with 10 Units/ml human insulin, 85%; fetal bovine serum, 15%
Temperature: 37.0°C
|
|
|
Subcultivation Ratio: A subcultivation ratio of 1:2 to 1:4 is recommended
Medium Renewal: Every 2 to 3 days
Remove medium, and rinse with 0.25% trypsin, 0.03% EDTA solution. Remove the solution and add an additional 1 to 2 ml of trypsin-EDTA solution. Allow the flask to sit at room temperature (or at 37C) until the cells detach.
Add fresh culture medium, aspirate and dispense into new culture flasks.
|
|
|
culture medium 95%; DMSO, 5%
|
|
|
20 hrs
|
|
|
Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001
recommended serum:ATCC 30-2020
|
|
|
50655: Jaffee EM, et al. Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials. Cancer J. Sci. Am. 4: 194-203, 1998. PubMed: 9612602
|
|
|
ATCC® Number: CRL-2551? Price: $417.00
Designations: Panc 08.13
Depositors: EM Jaffee
Biosafety Level: 1
Shipped: frozen
Medium & Serum: See Propagation
Growth Properties: adherent
Organism: Homo sapiens (human)
Morphology: epithelial
Source: Organ: pancreas
Disease: adenocarcinoma
Cellular Products: cytokeratins 7 and 18 [50655]
Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Tumorigenic: Yes
Oncogene: K-ras +
Antigen Expression: MHC class I +; MHC class II - [50655]
DNA Profile (STR): Amelogenin: X
CSF1PO: 11
D13S317: 13
D16S539: 13
D5S818: 13,14
D7S820: 11
THO1: 6,9.3
TPOX: 8,12
vWA: 18
Age: 85 years
Gender: male
Ethnicity: White
Comments: Panc 08.13 is a pancreatic adenocarcinoma epithelial cell line derived in 1995 from a primary tumor removed from the head-of-the-pancreas of a male with pancreatic adenocarcinoma.
The cell line exhibits a K-ras oncogene mutation at codon 12 where a GGT --> GAT mutation resulted in substitution of aspartic acid for glycine. [50655]
The cells have a reported plating efficiency of 40%. [50655]
Propagation: ATCC complete growth medium: RPMI 1640 medium with 2 mM L-glutamine adjusted to contain 1.5 g/L sodium bicarbonate, 4.5 g/L glucose, 10 mM HEPES, and 1.0 mM sodium pyruvate and supplemented with 10 Units/ml human insulin, 85%; fetal bovine serum, 15%
Temperature: 37.0°C
Subculturing: Subcultivation Ratio: A subcultivation ratio of 1:2 to 1:4 is recommended
Medium Renewal: Every 2 to 3 days
Remove medium, and rinse with 0.25% trypsin, 0.03% EDTA solution. Remove the solution and add an additional 1 to 2 ml of trypsin-EDTA solution. Allow the flask to sit at room temperature (or at 37C) until the cells detach.
Add fresh culture medium, aspirate and dispense into new culture flasks.
Preservation: culture medium 95%; DMSO, 5%
Doubling Time: 20 hrs
Related Products: Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001
recommended serum:ATCC 30-2020
References: 50655: Jaffee EM, et al. Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials. Cancer J. Sci. Am. 4: 194-203, 1998. PubMed: 9612602
Related Links
NCBI Entrez Search
Make a Deposit
Frequently Asked Questions
Material Transfer Agreement
Technical Support
Related Cell Culture Products
